Ovid Therapeutics Management
Management criteria checks 3/4
Ovid Therapeutics' CEO is Jeremy Levin, appointed in Mar 2015, has a tenure of 9.08 years. total yearly compensation is $2.14M, comprised of 29.3% salary and 70.7% bonuses, including company stock and options. directly owns 5.16% of the company’s shares, worth €10.56M. The average tenure of the management team and the board of directors is 2.8 years and 4.1 years respectively.
Key information
Jeremy Levin
Chief executive officer
US$2.1m
Total compensation
CEO salary percentage | 29.3% |
CEO tenure | 9.1yrs |
CEO ownership | 5.2% |
Management average tenure | 2.8yrs |
Board average tenure | 4.1yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Dec 31 2023 | US$2m | US$625k | -US$52m |
Sep 30 2023 | n/a | n/a | -US$49m |
Jun 30 2023 | n/a | n/a | -US$49m |
Mar 31 2023 | n/a | n/a | -US$51m |
Dec 31 2022 | US$3m | US$607k | -US$54m |
Sep 30 2022 | n/a | n/a | -US$68m |
Jun 30 2022 | n/a | n/a | -US$66m |
Mar 31 2022 | n/a | n/a | -US$67m |
Dec 31 2021 | US$847k | US$584k | US$120m |
Sep 30 2021 | n/a | n/a | US$123m |
Jun 30 2021 | n/a | n/a | US$117m |
Mar 31 2021 | n/a | n/a | US$110m |
Dec 31 2020 | US$2m | US$560k | -US$81m |
Sep 30 2020 | n/a | n/a | -US$76m |
Jun 30 2020 | n/a | n/a | -US$76m |
Mar 31 2020 | n/a | n/a | -US$67m |
Dec 31 2019 | US$3m | US$530k | -US$60m |
Sep 30 2019 | n/a | n/a | -US$56m |
Jun 30 2019 | n/a | n/a | -US$53m |
Mar 31 2019 | n/a | n/a | -US$53m |
Dec 31 2018 | US$3m | US$530k | -US$52m |
Sep 30 2018 | n/a | n/a | -US$50m |
Jun 30 2018 | n/a | n/a | -US$46m |
Mar 31 2018 | n/a | n/a | -US$44m |
Dec 31 2017 | US$2m | US$515k | -US$65m |
Compensation vs Market: Jeremy's total compensation ($USD2.14M) is above average for companies of similar size in the German market ($USD691.02K).
Compensation vs Earnings: Jeremy's compensation has been consistent with company performance over the past year.
CEO
Jeremy Levin (70 yo)
9.1yrs
Tenure
US$2,136,546
Compensation
Dr. Jeremy Max Levin, BA Zoology, DPhil, MB BChir, serves as Director of Graviton BioScience Corporation from May 2023. He has been the Chief Executive Officer of Ovid Therapeutics Inc. since March 2015 an...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
President | 9.1yrs | US$2.14m | 5.16% $ 10.6m | |
Chief Business and Financial Officer | 2.8yrs | US$1.08m | 0.019% $ 39.8k | |
General Counsel | 5.1yrs | US$1.07m | 0.018% $ 37.4k | |
Chief Operating Officer | 2.8yrs | US$1.23m | 0.0039% $ 8.0k | |
Chief Human Resources Officer | 1.7yrs | no data | no data | |
Senior Vice President of Global Manufacturing & CMC QA | 8.1yrs | US$1.18m | no data | |
Senior Vice President of Regulatory Affairs | 2.8yrs | no data | no data | |
Senior Vice President of Clinical Development | 2.8yrs | no data | no data | |
Chief Strategy Officer | 1.7yrs | no data | no data | |
Chief Medical Officer | 1.2yrs | no data | no data | |
Head of Epilepsy Research | 1.2yrs | no data | no data | |
Chief Scientific Officer | less than a year | no data | no data |
2.8yrs
Average Tenure
55yo
Average Age
Experienced Management: 1OT's management team is considered experienced (2.8 years average tenure).
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
President | 10yrs | US$2.14m | 5.16% $ 10.6m | |
Chairman of the Scientific & Clinical Advisory Board | 3yrs | no data | no data | |
Independent Director | 6.8yrs | US$86.66k | 0% $ 0 | |
Lead Independent Director | 8.4yrs | US$104.16k | 0% $ 0 | |
Independent Director | 2.8yrs | US$79.16k | 0% $ 0 | |
Member of Scientific & Clinical Advisory Board | 7.3yrs | no data | no data | |
Member of the Scientific & Clinical Advisory Board | 2.9yrs | no data | no data | |
Independent Director | 8.6yrs | US$91.66k | 0.028% $ 57.8k | |
Independent Director | 2.5yrs | US$71.66k | 0% $ 0 | |
Member of Scientific & Clinical Advisory Board | 2.7yrs | US$1.59m | no data | |
Member of Scientific & Clinical Advisory Board | 4.1yrs | no data | no data |
4.1yrs
Average Tenure
67.5yo
Average Age
Experienced Board: 1OT's board of directors are considered experienced (4.1 years average tenure).